Manufacturing Patents for Biosimilar Products
Manufacturing patents will play a larger role than molecule patents within the biologics development process, and these will also be a factor in terms of bringing complex products to market, argued Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.
Manufacturing patents will play a larger role than molecule patents within the biologics development process, and these will also be a factor in terms of bringing complex products to market, argued Steven Lucio, senior director, Clinical Solutions and Pharmacy Program Development at Novation.
This video was shot at the 2013 Academy of Managed Care Pharmacy in San Antonio, Texas.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
September 18th 2025
- FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
September 17th 2025